Marjorie Westervelt, PhD, MPH, Darius Billingsley, MD, Maya London, and Tonya Fancher, MD, MPH
Retention, student progression, and career advancement milestones are at least as important as admissions in promoting just medical education opportunity.
AMA J Ethics. 2021;23(12):E937-945. doi:
10.1001/amajethics.2021.937.
Barbara Barzansky, PhD, MHPE, Robert B. Hash, MD, MBA, Veronica Catanese, MD, MBA, and Donna Waechter, PhD
Diversity standards in medical education accreditation do not guarantee diversity but stimulate schools’ activities to recruit and retain diverse students and faculty.
AMA J Ethics. 2021;23(12):E946-952. doi:
10.1001/amajethics.2021.946.
Lyubov Slashcheva, Rick Rader, MD, and Stephen B. Sulkes, MD
Designation of people with intellectual and developmental disabilities as a medically underserved population would not solve problems of access to care.
AMA J Ethics. 2016;18(4):422-429. doi:
10.1001/journalofethics.2016.18.4.pfor1-1604.
Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021;23(5):E405-409. doi:
10.1001/amajethics.2021.405.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"